Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis